Introduction
Alterations in cellular metabolism represent a distinguishing and actionable feature of cancer cells, in contrast to surrounding, otherwise healthy, tissues. While many tumors exhibit elevated metabolism of glucose and glutamine [1] [2] [3] [4] , elevated cholesterol metabolism is also a characteristic of many human tumors [5, 6] . Translocator protein (TSPO) is an 18-kDa protein, primarily localized to mitochondria, that facilitates cholesterol transport and metabolism. TSPO is highly expressed in numerous solid tumors, including those of the central nervous system [7, 8] , oral cavity [9] , liver [10, 11] , breast [12, 13] , and colon [14] [15] [16] , where elevated levels tend to be associated with poor outcome. These findings support TSPO as a potentially important biomarker in oncology and suggest the utility of tumor-selective TSPO ligands for cancer imaging with positron emission tomography (PET).
In prior studies, we have shown that high-affinity, pyrazolopyrimidine TSPO PET probes such as [ [18, 19] , as well as contemporary TSPO ligands based upon other unique scaffolds [20] [21] [22] , can be used to visualize TSPO expression in tumors in preclinical settings (Fig. 1) . The novel ligand [ 18 F]VUIIS1008 proved to be a highly potent TSPO PET ligand, exhibiting a 36-fold enhancement in TSPO affinity, compared to 1, and high radiochemical yield and specific activity.
More recently, further refinement of the SAR inherent to the pyrazolopyrimidine core led us to the new compounds reported here, N,N-diethyl-2-(7-ethyl-2-(4-(2-fluoroethoxy)-phenyl)-5-methylpyrazolo [1,5-a] pyrimidin-3-yl)acetamide (VUIIS1009A (3A)) and N,N-diethyl-2-(5-ethyl-2-(4-(2-fluoroethoxy)phenyl)-7-methylpyrazolo [1,5-a] pyrimidin-3-yl)acetamide (VUIIS1009B (3B)) ( Fig. 1 ). Both compounds share the common pyrazolopyrimidinal core with 1 and 2 but are unique 5-and 7-regioisomers bearing pendant methyl or ethyl moieties. These seemingly minor structural variations led to exceptional (picomolar) TSPO binding affinities for 3A and 3B, which were 20-fold greater than 2 and 500-fold that of 1, prompting our subsequent further characterization of these ligands.
Materials and Methods
Chemical Preparation and Characterization [ 3 H]PK11195 was purchased from PerkinElmer. Phosphate-buffered saline and CytoScint ES Liquid Scintillation Cocktail were purchased from MP Biomedicals. 2,4-Hexanedione was purchased from Accel Pharmtech, USA. All other synthesis reagents were purchased from Sigma-Aldrich and used as received, unless noted otherwise. Ligands 3A and 3B and radioligand precursors (6A, 6B) were prepared (Supplemental Fig. 1 ). Compound characterization was performed using 1 H-NMR, 13 C-NMR, high-resolution mass spectrometry (HRMS), and X-ray diffraction on select compounds (see Supplemental Information).
In Vitro Binding Assay
Ligand binding experiments were conducted in C6 glioma cell lysates as previously described [17, 18] , using 3A and 
NMR Titration
15 N-labeled mitochondrial TSPO (mTSPO) was expressed in BL21(DE3) Escherichia coli in M9 minimal media, solubilized, and purified with dodecylphosphocholine (DPC) detergent, as adapted from previous publications [23, 24] . 2D 1 H-15 N heteronuclear single quantum coherence (HSQC) spectra of mTSPO with/without ligands (5.0 mM) were recorded on an 800-MHz NMR spectrometer at 42°C with 0.2-mM TSPO in ∼2 % DPC (w/v), 25-mM MES buffer, pH 6.0, and 100 mM NaCl. Ligands tested were 1, 3A, 3B, and PK11195. Spectra were processed with NMRPipe and analyzed using Sparky.
Animals
All studies involving mice and rats were conducted in compliance with federal and institutional guidelines. C57BL/6 male mice (∼25 g) were used for healthy biodistribution studies. For glioma model studies, healthy male Wistar rats (∼280 g) were stereotactically inoculated in the right hemisphere with 1.0 × 10 5 C6 glioma cells (American Type Culture Collection; Manassas, VA, USA) using a Hamilton syringe in a stereotactic apparatus (Stoelting) 2 weeks prior to imaging. Coordinates used for cell injection were 4 mm lateral to the bregma and 5 mm in depth to the dural surface. Rats were then affixed with venous and arterial catheters prior to the MRI and PET/CT studies. 
Radioligand Preparation

MRI, PET, and CT Imaging
MRI was used to localize all C6 tumors using previously published method [17] . PET/CT was initiated within 24 h of MRI in rats with confirmed tumors (n = 31 5, 8, 20 , and 45 min while 200 μl were drawn at 2, 12, 30, and 60 min for metabolite corrections. The dynamic PET acquisition was divided into twelve 10-s frames for the first 2 min, three 60-s frames for the following 3 min, and seventeen 300-s frames for the duration of the scan. The raw data within each frame were then binned into 3D sinograms, with a span of 3 and ring difference of 47. The sinograms were reconstructed into tomographic images (128 × 128 × 95) with voxel sizes of 0.095 × 0.095 × 0.08 cm 3 . 
TLC Radiometabolite Analysis
Plasma radiometabolites of [ 18 F]3A and [ 18 F]3B were evaluated using radio-thin-layer chromatography (radio-TLC) according to the published methods [19] .
Histology
Whole brains were harvested and fixed in 4 % buffered formalin for 48 h, followed by paraffin embedding for histology and immunohistochemistry (IHC). Tissue sections (5.0 μm) were stained with TSPO-specific rabbit polyclonal anti-rat/anti-mouse antibody (Novus Biologicals, LLC; Littleton, CO). Immunoreactivity was assessed using a horseradish peroxidase detection kit (Dako, Glostrup, Denmark). Hematoxylin and eosin (H&E) staining was used to evaluate cell density and tumor localization. Sections were visualized and documented using bright field microscopy (Leica Microsystems, Inc.; Buffalo Grove, IL).
Image Analysis and Modeling
For PET imaging of glioma-bearing rats, time-activity curves (TACs) were generated by manually drawing 3D volumes of interest over tumor and contralateral brain using ASIPro (Siemens). The arterial input function (AIF) was computed from plasma sampling manually (15 μl) during imaging and corrected for metabolism of the parent ligand. In this study, a two-tissue, four-rate-constant kinetic model was explored with the PMOD software package as metrics to reflect [
18 F]3A/B pharmacokinetics in reference tissues, such as tumor and brain. Model fit was evaluated by chi-squared (χ 2 ) values and visual inspection. For PET imaging of mice, ROIs corresponding to heart, lung, kidney, and liver were manually drawn using ASIPro. We applied two approaches to calculate the total distribution volume (V T ) of the radiotracer, including the Logan plot analysis [25] and the kinetic analysis using a two-tissue compartment model [26] . The metabolite-corrected plasma curve was used as an input function in a plasma plus two-tissue compartment model.
Biodistribution
Biodistribution of [
18 F]3A/B was characterized in healthy C57BL/6 male mice. Calculation of %ID/cc for a variety of tissues was based on the cut-and-count results 60 min after probe injection. In order to characterize binding specificity in healthy tissues, we also evaluated biodistribution in a displacement assay, administering non-radioactive 3A or 3B (10 mg/kg) 30 min after corresponding radioligand injection. Tissue %ID/cc was calculated based on cut-and-count results 60 min post probe injection. The target tissues were then resected and weighed, followed by radioactivity measurement in a well counter (Capintec; NJ).
Plasma Protein Binding
The degree of compound bound to plasma protein was determined with the equilibrium dialysis method [27] at the Vanderbilt High-Throughput Screening Core Facility. Detailed method is included in Supplemental Information.
Results
Chemical Synthesis of 3A and 3B and Radiofluorination Precursors 6A and 6B
Synthesis of 3A and 3B began with condensation of the pyrazole core of 4 with 2,4-hexanedione (Supplemental Fig. 1 ). Subsequent acid cleavage of the methoxy groups yielded intermediates 5A and 5B, which were resolved using HPLC and crystallized for structure determination via X-ray crystallography (Fig. 2) . The X-ray structure of compound 5A displayed the 5-methyl and 7-ethyl substitution patterns on the pyrazolopyrimidinal ring, while compound 5B displayed the reverse, 5-ethyl and 7-methyl. Reaction of 5A and 5B with tosylated fluoroethanol under microwaveassisted organic synthesis (MAOS) conditions [17] [18] [19] gave compounds 3A and 3B, respectively (Fig. 1) . The corresponding radiochemistry precursors 6A and 6B were synthesized in analogous fashion, with 5A and 5B coupled to di-tosylated glycol using MAOS. For subsequent in vitro assay testing, 3A and 3B served as the corresponding nonradioactive (fluorine-19) analogs.
Specific Binding of 3A and 3B to TSPO in Cell Line Homogenates
To evaluate TSPO binding of 3A and 3B in vitro, radioligand displacement was performed in C6 glioma cell lysate using [ 3 H]PK11195 [17, 22] , with affinities expressed as IC 50 (nM) (Fig. 2) . Both 3A and 3B competitively displaced [18, 19] and DPA-714 (10.9 nM) [17, 18] .
Protein Binding Pockets for 3A and 3B in Mammalian TSPO Jaremko et al. recently reported that the structure of TSPO could be stabilized in the presence of PK11195, yielding a tight bundle of five transmembrane α helices that forms a hydrophobic binding pocket to accept PK11195. 2D 1 H-15 N HSQC NMR analysis of this structure allowed for a highquality spectrum of the ligand-bound state of the protein [23] . To investigate the differences in the structure of TSPO when bound to 3A and 3B, 2D HSQC spectroscopy was used to observe structural features of each ligand-bound state of the protein and compared to DPA-714 and PK11195. In a 2D 1 H-15 N HSQC spectrum, peaks arise from amides in the protein backbone and side chains, which are highly dependent on the chemical environment surrounding each amide group. This allows the HSQC spectrum to serve as a solution-phase fingerprinting method of protein structure.
The ligand-free TSPO reconstituted in DPC micelles displayed the same narrow dispersed spectrum as previously reported (Fig. 3a) . Addition of PK11195 (Fig. 3b) , as well as DPA-714 (Fig. 3c) , resulted in highly dispersed spectra, with a new set of peaks representing signals from the ligandbound state of the protein. The DPA-714 spectrum showed significant differences in chemical shift perturbation when compared with the PK11195 spectrum (Fig. 3b) , which are possibly due to the different chemical groups from the two compounds interacting with the protein, the different ligandinduced protein conformational changes, and the ligandbinding pocket formed for DPA-714 being different from that of PK11195. Titrating 3A or 3B into the TSPO also gave improved spectral dispersion, though in our hands, of the four compounds tested, only 3B completely saturated the ligand-bound state. No obvious changes in chemical shift perturbation were observed between DPA-714, 3A, or 3B (Fig. 3c) [17-19, 21, 22] . Preclinical gliomas were first localized using T 2 -weighted MRI, which exhibited the typical hyperintensity in the right hemisphere due to longer T 2 relaxation times compared to surrounding normal brain tissue (Fig. 4a) . Similar to (Fig. 4b, c , e, f, Supplemental Fig. 2 ). For validation of PET, following sacrifice, imaging-matched brains were processed for H&E staining (Fig. 4d ) and TSPO IHC (Fig. 4d, inset) (Fig. 4g, h ). Analysis of the last 30 min of uptake (Fig. 4g, h ) indicated a twofold higher %ID/cc for [
18 F]3B (n = 6) ( Fig. 4h) To evaluate the binding specificity of [ 18 F]3A/B, displacement studies in C6 glioma-bearing rats were performed using 3A and 3B, respectively. During a typical 60-min dynamic PET study, an excess of 3A or 3B (10 mg/kg) was administrated intravenously 30 min after injection of the corresponding radioligand. Summation of the first 30 min of the dynamic scan demonstrated typical uptake characteristics for both [ 18 F]3A ( Fig. 5a and Supplemental Fig. 4a, c) and [ 18 F]3B ( Fig. 5b and Supplemental Fig. 4e, g ). Summation of the final 30 min of the scan showed near-complete displacement for [ 18 F]3B (Fig. 5e, Supplemental Fig. 4f,  h ), while only partial displacement for [ 18 F]3A (Fig. 5b,  Supplemental Fig. 4b, d ). TAC analysis indicated 80 % displacement for [ 18 F]3B (Fig. 5f ), while only 33 % displacement for [ 18 F]3A (Fig. 5c ) at the end of the scan. Fig. 5a ), quantitative analysis and pharmacokinetic parameter estimation were performed by fitting the TACs derived from the 60-min dynamic PET data (Supplemental Fig. 5b, c) .
Based on this model, we estimated the values for the four kinetic parameters k 1 , k 2 , k 3 , and k 4 ( Table 1) . Probe binding potential (BP ND ) was calculated as k 3 /k 4 , denoting the ratio at equilibrium of specifically bound radioligand to that of non-displaceable radioligand in tissue.
This state of equilibrium is reached at approximately 40 min post radiotracer injection as evident by the plasma and tissue TACs (Supplemental Fig. 5 ). The BP ND calculated in Table 1 Logan plot analysis demonstrated a total distribution volume (V T ) for [ 18 F]3B that is six times higher in the tumor and nearly twice as high in the brain compared to [ 18 F]3A (see Table 1 ). The difference in V T between the two radiotracers was also confirmed via compartment modeling as displayed in Table 1 . Taken together, we not only obtain higher uptake of [ 18 F]3B in tumor compared to [ 18 F]3A but also higher contrast-tobackground ratio; tumor-to-normal brain = 12.7 ± 5.3 for [
18 F]3B and 3.7 ± 0.9 for [ 18 F]3A (see Table 1 ).
Biodistribution in Mice
Biodistribution of the two probes in healthy mice was characterized with cut-and-count analysis. We found a similar distribution pattern between [ 18 F]3A and [ 18 F]3B, with high absorption in TSPO-abundant tissues like lung, kidney, spleen, and heart; medium absorption in liver and colon; and low absorption in TSPO-deficient tissues like pancreas, muscle, and brain (Fig. 6a) . Further analyses of the binding specificity and reversibility in healthy tissue were performed in displacement assays. Figure 6b , c, respectively, demonstrates that [
18 F]3A and [ 18 F]3B could be displaced from the lung, liver, heart, kidney, and pancreas with their corresponding cold analogs.
Whole Body PET Imaging with [ 18 F]3B
Whole body 60-min dynamic scan was performed with [ 18 F]3B in a healthy Wistar rat (Supplemental Fig. 7) . In this analysis, we observed a specific absorption of the probe in lung, kidney, heart, and liver (Supplemental Fig. 7a, b) . The PET image is corresponding to the TACs obtained using TAC analysis as shown in Supplemental Fig. 7c .
Plasma Protein Binding Affinity
Higher k 1 /k 2 values indicate a higher extraction rate for the probe in plasma, which can be associated with the plasma protein binding affinity. As shown in Supplemental Fig. 6 , both 3A and 3B exhibited lower unbound fraction than DPA-714. Further, 3B exhibited 0.54 % more unbound fraction compared with 3A, which likely contributed to the enhanced tissue delivery observed.
Discussion
Our prior research has explored TSPO as a target for molecular imaging of cancer [14, 17, 22, 29, 30] . We have reported preclinical utilization of pyrazolopyrimidine PET probes for quantitative assessment of TSPO expression in glioma, which include the previously reported [ 18 F]DPA-714 [17] and the novel TSPO ligand [ 18 F]VUIIS1008 [18, 19] developed in our lab. In prior studies using these tracers, C6 tumors could be detected from the surrounding normal brain; moreover, quantitative analyses of the PET data agreed with ex vivo measures of TSPO levels [17] [18] [19] . This work also showed that improved TSPO affinity and PET imaging characteristics were a result of targeted modification of the pyrazolopyrimidine scaffold, specifically at the 5-and 7-positions. These studies prompted our lab to continue development of novel TSPO PET probes with improved properties for cancer imaging. In this study, further exploration of the 5-and 7-positions on the pyrazolopyrimidine ring yielded two novel and highaffinity TSPO ligands, which are VUIIS1009A (3A) and VUIIS1009B (3B). The structural modifications of 3A (5-methyl, 7-ethyl) and 3B (5-ethyl, 7-methyl) 
Conclusions
In this study, we report discovery of two high-affinity TSPO PET ligands and evaluation of their performance in preclinical glioma imaging. VUIIS1009A (3A) and VUIIS1009B (3B) exhibited exceptional binding affinity to TSPO and shared a common binding pocket within mTSPO. However, taking advantage of increased plasma-to-tumor extraction efficiency, [ 18 F]VUIIS1009B exhibited superior imaging performance compared with [ 18 F]VUIIS1009A. These studies highlight the important role of tissue delivery and may expand opportunities to utilize [ 18 F]VUIIS1009B
as a promising PET tracer for precision medicine deployment.
